Product Description
AVC-101 is a CD123 CAR-T cell therapy for the treatment of acute myeloid leukemia. (Sourced from: https://avencell.com/pipeline-3)
Mechanisms of Action: CAR-T, CD123
Novel Mechanism: Yes
Modality: Autologous CAR-T
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AvenCell
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Acute Myeloid Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|